DAWN Stock Day One Biopharmaceuticals (DAWN, $6.61) Moving Average Convergence Divergence (MACD) Histogram turned positive on July 1, 2025

GET DAILY SIGNALS

Get AI intraday signals

DAWN - Day One Biopharmaceuticals

MACD signal

View

Odds of UP Trend

Price: $6.61

Daily change: +$0.11 (+1.69%)

Daily volume: 1.4M

Capitalization: $670M

Industry: Biotechnology

DAWN in -2.77% downward trend, declining for three consecutive days on June 20, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where DAWN declined for three days, in of 252 cases, the price declined further within the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DAWN as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

DAWN moved below its 50-day moving average on June 10, 2025 date and that indicates a change from an upward trend to a downward trend.

DAWN broke above its upper Bollinger Band on June 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where DAWN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for DAWN just turned positive on July 01, 2025. Looking at past instances where DAWN's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DAWN advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 123 cases where DAWN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.374) is normal, around the industry mean (16.395). P/E Ratio (0.000) is within average values for comparable stocks, (58.556). DAWN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.311). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (3.903) is also within normal values, averaging (259.528).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. DAWN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DAWN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.